Feeds:
Posts
Comments

Posts Tagged ‘MDV3100’

URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>

Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.

Read Full Post »

URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life. READ MORE>

Read Full Post »

MODERN MEDICINE: TWO compounds – the diarylthiohydantoins RD162 and MDV3100 – are effective in treating advanced prostate cancer resistant to first-line treatments, according to research published online April 9 in Science. READ MORE>

Read Full Post »